4-hydrazino-2-methyl-6-phenylpyrimidine | 25194-59-6

• 分子结构分类: 有机化合物 - 有机杂环化合物 - 二嗪类
• 英文名称: 4-hydrazino-2-methyl-6-phenylpyrimidine
• 英文别名: 4-hydrazinyl-2-methyl-6-phenylpyrimidine；(2-methyl-6-phenylpyrimidin-4-yl)hydrazine
• CAS: 25194-59-6
• 化学式: C₁₁H₁₂N₄
• 分子量: 200.243
• InChiKey: XQAHEWMHCLJMDV-UHFFFAOYSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  1.8
• 重原子数：
  15
• 可旋转键数：
  2
• 环数：
  2.0
• sp3杂化的碳原子比例：
  0.09
• 拓扑面积：
  63.8
• 氢给体数：
  2
• 氢受体数：
  4

反应信息

• 作为反应物：
  描述：

  4-hydrazino-2-methyl-6-phenylpyrimidine 在 溶剂黄146 、 sodium nitrite 作用下， 以 氘代氯仿 、 水 为溶剂， 反应 1.0h， 生成 4-azido-2-methyl-6-phenylpyrimidine
  参考文献：
  名称：

  2,6-二取代 4-叠氮嘧啶：通过核磁共振光谱法对叠氮四唑重排的合成、动力学和热力学研究

  摘要：

  通过 NOESY/EXSY 和 DNMR 确定一系列 2,6-二取代 4-叠氮嘧啶的互变异构四唑-叠氮重排的热力学和动力学参数：ΔH = 15-28 kJ mol-1；ΔS = 47—65 J mol–1 К–1；Еa = 93—117 kJ mol–1；lgA = 15.1—18.9。它们取决于取代基的电子特性和溶剂的极性。

  DOI：

  10.1007/s11172-017-1986-2

文献信息

• New heterocyclic compounds
  申请人：Sharma Ganapavarapu V.R.

  公开号：US20080221103A1

  公开（公告）日：2008-09-11

  Provided herein are heterocyclic compounds of the general formula (I), their derivatives, analogs, tautomeric forms, stereoisomers, polymorphs, hydrates, solvates, pharmaceutically acceptable salts and compositions, metabolites and prodrugs thereof, wherein R 1 , R 2 , R 3 , R 4 and R 5 are as described herein. Further described herein in particular are heterocyclic compounds of the formula (I) for treating various diseases. and disorders by administering in a patient one or more TNF-α, Thromboxane synthase, 5-LOX, and PDE4 inhibitors. In particular described herein are methods for treating immunological diseases, inflammation, pain disorder, rheumatoid arthritis; osteoporosis; multiple myeloma; uveititis; acute and chronic myelogenous leukemia; ischemic heart disease; atherosclerosis; cancer; ischemic-induced cell damage; pancreatic beta cell destruction; osteoarthritis; rheumatoid spondylitis; gouty arthritis; inflammatory bowel disease; adult respiratory distress syndrome (ARDS); psoriasis; Crohn's disease; allergic rhinitis; ulcerative colitis; anaphylaxis; contact dermatitis; muscle degeneration; cachexia; asthma; bone resorption diseases; ischemia reperfusion injury; brain trauma; multiple sclerosis; sepsis; septic shock; toxic shock syndrome; fever, and myalgias due to infection and diseases mediated by HIV-1; HIV-2; HIV-3; cytomegalovirus (CMV); influenza; adenovirus; the herpes viruses (including HSV-1, HSV-2) and herpes zoster viruses in a mammal comprising administering an effective amount of a compound of formula (I).

  本文提供了一般式(I)的杂环化合物，它们的衍生物、类似物、互变异构体、立体异构体、多晶形态、水合物、溶剂合物、药学上可接受的盐和组合物、代谢产物及其前药，其中R1、R2、R3、R4和R5如本文所述。特别在此描述了一般式(I)的杂环化合物，用于治疗各种疾病和疾病，通过在患者中给予一种或多种TNF-α、血栓素合成酶、5-LOX和PDE4抑制剂。特别在此描述了治疗免疫性疾病、炎症、疼痛障碍、类风湿性关节炎；骨质疏松症；多发性骨髓瘤；葡萄膜炎；急性和慢性骨髓性白血病；缺血性心脏病；动脉粥样硬化；癌症；缺血性细胞损伤；胰岛素β细胞破坏；骨关节炎；类风湿脊柱炎；痛风性关节炎；炎症性肠病；成人呼吸窘迫综合症（ARDS）；银屑病；克罗恩病；过敏性鼻炎；溃疡性结肠炎；过敏性休克；接触性皮炎；肌肉退化；虚弱症；哮喘；骨吸收疾病；缺血再灌注损伤；脑外伤；多发性硬化；败血症；脓毒性休克；中毒性休克综合征；发热，以及由HIV-1；HIV-2；HIV-3；巨细胞病毒（CMV）；流感病毒；腺病毒；单纯疱疹病毒（包括HSV-1、HSV-2）和带状疱疹病毒介导的感染和疾病在哺乳动物中，包括给予一种一般式(I)化合物的有效剂量。
• Antiproliferative Pyrimidyl, Fused Pyrimidyl and Pyrimidyl Hydrazones
  申请人：Healey Brian

  公开号：US20080287474A1

  公开（公告）日：2008-11-20

  The present invention is related to a novel series of pyrimidyl or fused pyrimidyl hydrazones. Compounds of Formula (I) wherein A is selected from the group consisting of Formulas (A1), (A2), (A3), (A4), (A5) are useful for the treatment and/or prevention of a proliferative disease.

  本发明涉及一种新型的嘧啶基或融合嘧啶基肼酮系列。式（I）的化合物，其中A选自公式（A1）、（A2）、（A3）、（A4）、（A5）的群组，对于治疗和/或预防增生性疾病是有用的。
• Antiproliferative pyrimidyl, fused pyrimidyl and pyrimidyl hydrazones
  申请人：Merck Serono SA

  公开号：US08288398B2

  公开（公告）日：2012-10-16

  The present invention is related to a novel series of pyrimidyl or fused pyrimidyl hydrazones. Compounds of Formula (I) wherein A is selected from the group consisting of Formulas (A1), (A2), (A3), (A4), (A5) are useful for the treatment and/or prevention of a proliferative disease.

  本发明涉及一种新型的嘧啶基或融合嘧啶基腙类化合物系列。式(I)中，A选自公式(A1)、(A2)、(A3)、(A4)、(A5)组成的群，有用于治疗和/或预防增生性疾病的作用。
• ANTIPROLIFERATIVE PYRIMIDYL, FUSED PYRIMIDYL AND PYRIMIDYL HYDRAZONES
  申请人：HEALEY BRIAN

  公开号：US20120238575A1

  公开（公告）日：2012-09-20

  The present invention is related to a novel series of pyrimidyl or fused pyrimidyl hydrazones. Compounds of Formula (I) wherein A is selected from the group consisting of Formulas (A1), (A2), (A3), (A4), (A5) are useful for the treatment and/or prevention of a proliferative disease.

  本发明涉及一种新型的嘧啶基或融合嘧啶基腙类化合物系列。化合物的化学式（I）中，A选择自化学式（A1）、（A2）、（A3）、（A4）、（A5）的群组，对于治疗和/或预防增生性疾病有用。
• Copper(II) complexes with 4-(3,5-dimethyl-1H-pyrazol-1-yl)-2-methyl-6-phenylpyrimidine: Syntheses, crystal structures and catalytic activity in ethylene polymerization
  作者：Mark B. Bushuev、Viktor P. Krivopalov、Elizaveta V. Lider、Nina V. Semikolenova、Natalia V. Pervukhina、Dmitrii Yu. Naumov、Ludmila G. Lavrenova、Vladimir A. Zakharov、Stanislav V. Larionov

  DOI：10.1016/j.poly.2011.09.024

  日期：2012.1

  The copper(II) complexes CuLCl2 (1) and CuLBr2 (2), with the chelating pyrazolylpyrimidine ligand 4-(3,5-dimethyl-H-1-pyrazol-1-yl)-2-methyl-6-phenylpyrimidine (L), have been synthesized. A single crystal Xray diffraction study revealed that 1 and 2 have molecular mononuclear structures. The molecules of 1 and 2 form chains in the crystal structures of these compounds due to the formation of pi-pi-stacking interactions between the pyrimidine and the phenyl rings. The complexes, in combination with the co-catalyst methylaluminoxane (MAO), reveal catalytic activity in ethylene polymerization, while the free ligand L is inactive. (C) 2011 Elsevier Ltd. All rights reserved.